Briefing
Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).
At a median of 8.4 years from diagnosis to first sample, 8/83 (10%) were MRD-positive at any timepoint and 4/83 (5%) were positive at study entry. All 5 patients with distant metastatic recurrence were MRD-positive, with ctDNA lead times up to 37.6 months. Two of 8 MRD-positive patients had not recurred at latest follow-up.
- n: 103 enrolled; 83 with successful whole-exome sequencing and personalized assays; 219 plasma samples
- Assay: RaDaR (personalized, tumor-informed; 12-51 variants, median 36)